About
Leap Therapeutics
is focused on developing targeted and immuno-oncology therapeutics.
Leap’s most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with colorectal, esophagogastric, and gynecologic cancers. Leap also has FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development.
